TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01982019

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meal test taking and hormones measure including 26RFa
Description: Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meal test taking and hormones measure including 26RFa
Description: Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meal test taking and hormones measure including 26RFa
Description: Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
Study: NCT03192085

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SITA FAST VISUAL FIELD TEST
Description: Diagnostic test for glaucoma

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SITA FAST VISUAL FIELD TEST
Description: Diagnostic test for glaucoma

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SITA STANDARD VISUAL FIELD TEST
Description: Diagnostic test for glaucoma

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SITA STANDARD VISUAL FIELD TEST
Description: Diagnostic test for glaucoma
Study: NCT01475487

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Utrasound guided cricothyrotomy
Description: Utrasound guided cricothyrotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Utrasound guided cricothyrotomy
Description: Utrasound guided cricothyrotomy
Study: NCT01948401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: long-acting beta-agonist treatment
Study: NCT01495637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
Study: NCT04140058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron was administered 20 minutes prior to spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron was administered 20 minutes prior to spinal anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo of 10 mL normal saline was administered.
Study: NCT02992275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Modality Balance Intervention (MMBI)
Description: Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
Study: NCT06708442

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School-based CBT intervention
Description: School-based CBT intervention: a 3-day, 40-minute per day cognitive behavioral intervention. The intervention will take place in a school classroom in a format similar to offline classroom lectures and classroom interactions. The intervention will lead by one undergraduate student from the School of Psychological and Cognitive Sciences and one first-year doctoral student with training in clinical psychology. The content of the intervention was based on the theory of cognitive behavioral therapy for children, with a complete self-developed intervention manual, and three interventions targeting emotional awareness and management, thought recognition, and problem coping, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based CBT intervention
Description: School-based CBT intervention: a 3-day, 40-minute per day cognitive behavioral intervention. The intervention will take place in a school classroom in a format similar to offline classroom lectures and classroom interactions. The intervention will lead by one undergraduate student from the School of Psychological and Cognitive Sciences and one first-year doctoral student with training in clinical psychology. The content of the intervention was based on the theory of cognitive behavioral therapy for children, with a complete self-developed intervention manual, and three interventions targeting emotional awareness and management, thought recognition, and problem coping, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Narrative Technique (GNT) Writing
Description: Guided Narrative Technique (GNT) Writing : GNT writing is an intervention through writing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Writing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Narrative Technique (GNT) drawing
Description: Guided Narrative Technique (GNT) Drawing: GNT drawing is an intervention through drawing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Drawing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
Study: NCT06709729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump with closed-loop system
Description: Device: Usage of Insulin pump t:slim X2 with Control-IQ technology or MiniMed 780G with Smartguard technology in previous users of AndroidAPS
Study: NCT04092270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study: NCT04180085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept Injection
Description: 9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
Study: NCT01948401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: long-acting beta-agonist treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: long-acting beta-agonist treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
Study: NCT03211338

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with progesterone
Description: Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with progesterone
Description: Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with progesterone
Description: Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with progesterone
Description: Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
Study: NCT02403323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: 105 mg etrolizumab subcutaneous administration once every 4 weeks
Study: NCT00506519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin alfa (INN name)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin alfa (INN name)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Study: NCT04215978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered as specified in the treatment arm
Study: NCT03211338

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture without progesterone
Description: Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture without progesterone
Description: Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture without progesterone
Description: Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture without progesterone
Description: Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with growth factors
Description: Culture of placental IMC cells with growth hormones only and analysis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with growth factors
Description: Culture of placental IMC cells with growth hormones only and analysis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with growth factors
Description: Culture of placental IMC cells with growth hormones only and analysis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with growth factors
Description: Culture of placental IMC cells with growth hormones only and analysis
Study: NCT02999399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brussel Sprouts
Description: Subjects are given \~150 g of Brussels sprouts once daily for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated Phenanthrene
Description: Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
Study: NCT04215978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered as specified in the treatment arm
Study: NCT02862899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermowire
Study: NCT01927341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
Study: NCT04215978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Administered as specified in the treatment arm
Study: NCT00596856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT
Description: The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT
Description: The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT
Description: The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
Study: NCT02883192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Zofran 4 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01397201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI
Study: NCT04046575

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: -15 fractions of treatment
Study: NCT01397201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903
Study: NCT04046575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Begins on day 1 of radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD Anderson Symptom Inventory (MDASI)-Plus module
Description: The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EuroQol (EQ-5D)
Description: The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-12
Description: The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
Study: NCT01948401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: chronic treatment with oral corticosteroids, high dose inhaled corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: chronic treatment with oral corticosteroids, high dose inhaled corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: additional 0.5 mg/kg orally for 7 days
Study: NCT01463709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseCure pulse generator and Derm-pulse electrode
Description: PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure
Study: NCT04427033

Intervention type: DEVICE
Intervention: Bone Conduction Implant
Description: Bonebridge system BCI 602

Intervention type: DEVICE
Intervention: Bone Conduction Implant
Description: Bonebridge system BCI 602

Intervention type: DEVICE
Intervention: Bone Conduction Implant
Description: Bonebridge system BCI 602
Study: NCT01007409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
Study: NCT05333653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continouse supportive care
Description: Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine care
Description: Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
Study: NCT02682134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylocaine
Description: First group were given xylocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Second group were given Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine and Dexamethasone
Description: Third group were given both Xylocaine and Dexamethasone
Study: NCT04038606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determination of acceptance and / or rejection of mastectomy
Description: Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of acceptance and / or rejection of mastectomy
Description: Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
Study: NCT04046575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOS Social Support Measure
Description: The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CES-D
Description: The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for ctDNA (optional)
Description: -Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for SCCA
Description: -Collected at pre-treatment, completion of therapy, and 6 month follow-up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Begins on day 1 of radiotherapy
Study: NCT03737734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.